Tenon Medical, INC Form 4 insider transactions

Robert K Weigle, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Kristine M Jacques, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Ivan Howard, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Stephen Hochschuler, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Richard Ferrari, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Kevin Williamson, Chief Financial Officer of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Richard Ginn, Chief Technology Officer and a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Steven M Foster, CEO and President and a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Chief Innovation Officer Wyatt D. Geist reports an indirect acquisition of 136,401 shares of Tenon Medical common stock following a milestone achievement.

Chief Commercial Officer Nathaniel Grawey reported an indirect acquisition of 68,201 shares of Tenon Medical common stock following a milestone achievement.

Tenon Medical CFO Kevin Williamson converted 1,041 restricted stock units into common stock on March 3, 2026, increasing his direct holdings.

Steven M. Foster, CEO and President of Tenon Medical, Inc., converted 140,936 restricted stock units into common stock, increasing his direct ownership.

Tenon Medical Director Stephen Hochschuler converted 10,732 restricted stock units into common stock and subsequently sold 3,327 shares to cover tax liabilities.

Tenon Medical Director Robert K. Weigle converted restricted stock units into common stock and subsequently sold shares to cover tax liabilities.

Tenon Medical's Chief Technology Officer, Richard Ginn, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

Tenon Medical Director Richard Ferrari converted 64,479 restricted stock units into common stock on January 1, 2026.

Tenon Medical Director Kristine M. Jacques converted 10,729 Restricted Stock Units into common stock on January 1, 2026.

Tenon Medical's CFO, Kevin Williamson, converted 58,987 restricted stock units into common stock and subsequently sold 18,518 shares to cover tax liabilities.

Tenon Medical, Inc. Director Ivan Howard converted 10,732 restricted stock units into common stock and subsequently sold 3,327 shares to cover tax obligations.

Ivan Howard, a Director at Tenon Medical, Inc., reported the conversion of restricted stock units into common stock on May 22, 2024, and a future conversion scheduled for May 22, 2025.

Tenon Medical, Inc. Director Robert K. Weigle converted restricted stock units into common stock, increasing his direct beneficial ownership.

Tenon Medical, Inc. director Kristine M. Jacques received a grant of 1,750 restricted stock units, vesting over three years.

Tenon Medical's CFO, Kevin Williamson, reported the grant of 6,250 Restricted Stock Units and the conversion of 2,083 RSUs into common stock.

Tenon Medical, Inc. CEO and President Steven M. Foster acquired 19,455 shares of common stock and warrants in a private investment, increasing his direct beneficial ownership.

Tenon Medical's Chief Innovation Officer, Wyatt D. Geist, increased his direct and indirect holdings through a private investment in public equity transaction.

Tenon Medical's Chief Commercial Officer, Nathaniel A. Grawey, increased his direct and indirect beneficial ownership through a private investment in public equity transaction.

Tenon Medical, Inc. CEO and President Steven M. Foster was granted 281,872 restricted stock units, vesting in two tranches in 2026.

Tenon Medical Director Stephen Hochschuler was granted 21,464 restricted stock units, vesting in two tranches in 2026.

Tenon Medical, Inc. Director Robert K. Weigle was granted 21,464 restricted stock units, vesting in two tranches in 2026.

Tenon Medical's Chief Technology Officer, Richard Ginn, was granted 253,153 restricted stock units, aligning his interests with future company performance.